• Login
    • Join
  • FOLLOW:
  • Subscribe Free
    • Magazine
    • eNewsletter
    Checkout
    • Magazine
    • News
    • Manufacturing
    • Packaging
    • Development
    • Compliance
    • Top 20
    • Directory
    • Microsites
    • Events
    • More
  • Magazine
  • News
  • Manufacturing
  • Packaging
  • Development
  • Compliance
  • Top 20
  • Directory
  • Microsites
  • Events
  • Current / Back Issue
    Features
    Editorial
    Columns
    Digital Edition
    eNewsletter Archive
    Our Team
    Editorial Guidelines
    Subscribe Now
    Advertise Now
    Top Features
    Biotechnology’s Role in Improving Stroke Outcomes

    CEO Spotlight: Marc Kikuchi

    Newsmakers: Darren Shirley

    Are You Prepared for the 2023 DSCSA Deadline?

    Rethinking the Changing Role of the CRO
    Breaking News
    Online Exclusives
    Industry News
    Collaborations & Alliances
    Promotions & Moves
    Trials & Filings
    Financial Reports
    Bio News & Views
    Custom Sourcing News
    Packaging & Tracking
    CRO News
    Live From Shows
    Top News
    BioIVT Acquires Scottish Drug-metabolizing Enzyme Manufacturer Cypex

    Schott Creates Stand-Alone Company for its Pharma Business

    Marken to Acquire Medical Courier Business of Cedra Express

    Porton’s New Crystallization and Drug Product Facility

    Thermo Fisher Expands NY Cell Culture Media Manufacturing Site
    APIs
    Aseptic Processing
    Cleaning Validation
    Clinical Trial Materials
    Cytotoxics and High Potency Manufacturing
    Equipment
    Excipients
    Extractables and Leachables
    Facilities
    Fill/Finish
    Lyophilization
    Parenterals
    Process Development
    Process Validation
    Risk Management
    Scale-up/ Technology Transfer
    Solid Dosage/ Creams/ Ointments

    Marken to Acquire Medical Courier Business of Cedra Express

    Porton’s New Crystallization and Drug Product Facility

    Thermo Fisher Expands NY Cell Culture Media Manufacturing Site

    Woodstock Sterile Solutions Fills Two Leadership Roles

    SmartLabs To Open New Facility in Philadelphia
    Capsules
    Cold Chain Management
    Injectables
    Logistics
    Serialization
    Solid Dosage / Semi-solids
    Supply Chain
    Vials

    Marken to Acquire Medical Courier Business of Cedra Express

    5 Key Features of Agile Pharmaceutical Packaging Supply Chains That Drive Results

    Novavax Expands Manufacturing Agreement with SK bioscience

    Lonza Continues to Lead the Market with Innovative Hard Empty Capsules

    Sharp Expands Reach to China Through Partnership with ClinsChain
    Analytical Services
    Bioanalytical Services
    Bioassay Developement
    Biologics, Proteins, Vaccines
    Biosimilars
    Chemistry
    Clinical Trials
    Drug Delivery
    Drug Development
    Drug Discovery
    Formulation Development
    Information Technology
    Laboratory Testing
    Methods Development
    Microbiology
    Preclinical Outsourcing
    R&D
    Toxicology

    Thermo Fisher Expands NY Cell Culture Media Manufacturing Site

    Thorne HealthTech, AstraZeneca Entend AI Discovery Alliance

    Gilead Sciences to Acquire MiroBio for $405M

    Amgen to Acquire ChemoCentryx for $3.7B

    BioNTech, Genmab Expand Global Strategic Oncology Collaboration
    Filtration & Purification
    GMPs/GCPs
    Inspections
    QA/QC
    Regulatory Affairs
    Validation

    Chime Biologics Receives Commercial Manufacturing License

    Automation Is Key to Meeting Demands in Pharmacovigilance

    UBC Acquires Examoto

    Responding to Consumer Complaints While Working with CMOs

    WuXi Vaccines Receives GMP Certificate from HPRA
    Companies
    Categories
    Corporate Capabilities
    Add New Company
    Contract Service Directory Companies
    Quotient Sciences

    CMC Pharmaceuticals

    IDT Biologika

    Kyongbo Pharmaceutical

    Vector Partners Limited
    Companies
    News Releases
    Posters
    Brochures
    Services
    Videos
    Case Study
    White Papers
    Jobs
    Contract Service Directory Companies
    Quotient Sciences

    CMC Pharmaceuticals

    IDT Biologika

    Kyongbo Pharmaceutical

    Vector Partners Limited
    Webinars
    Live From Shows
    • Magazine
      • Current / Back Issue
      • Features
      • Editorial
      • Columns
      • Editorial Guidelines
      • Subscribe Now
      • Advertise Now
      • Enewsletter Archive
      • Digital Edition
    • Directory
      • Companies
      • Categories
      • Corporate Capabilities
      • Add Your Company
    • Manufacturing
      • APIs
      • Aseptic Processing
      • Cleaning Validation
      • Clinical Trial Materials
      • Cytotoxics and High Potency Manufacturing
      • Equipment
      • Excipients
      • Extractables and Leachables
      • Facilities
      • Fill/Finish
      • Lyophilization
      • Parenterals
      • Process Development
      • Process Validation
      • Risk Management
      • Scale-up/ Technology Transfer
      • Solid Dosage/ Creams/ Ointments
      • cGMP Manufacture
    • Packaging
      • Capsules
      • Cold Chain Management
      • Injectables
      • Logistics
      • Serialization
      • Solid Dosage / Semi-solids
      • Supply Chain
      • Vials
    • Development
      • Analytical Services
      • Bioanalytical Services
      • Bioassay Developement
      • Biologics, Proteins, Vaccines
      • Biosimilars
      • Chemistry
      • Clinical Trials
      • Drug Delivery
      • Drug Development
      • Drug Discovery
      • Formulation Development
      • Information Technology
      • Laboratory Testing
      • Methods Development
      • Microbiology
      • Preclinical Outsourcing
      • R&D
      • Toxicology
    • Compliance
      • Filtration & Purification
      • GMPs/GCPs
      • Inspections
      • QA/QC
      • Regulatory Affairs
      • Validation
    • Top 25 Pharma & BioPharma
    • Contract Pharma Direct
    • Breaking News
    • Online Exclusives
    • Slideshows
    • Experts Opinions
    • Surveys
      • Outsourcing Survey
      • Salary Survey
    • Glossary
    • Videos
    • White Papers
    • Podcasts
    • Infographics
    • Supplier Microsite
      • Companies
      • News Releases
      • Posters
      • Brochures
      • Services
      • Videos
      • Case Study
      • White Papers
    • Contract Pharma Conference
      • Contract Pharma Conference
      • Speakers
      • Exhibitors
      • Conference Sessions
    • eBook
    • Webinars
    • Events
      • Industry Events
      • Live from Show Events
      • Webinars
    • Classifieds / Job Bank
      • Classifieds
      • Job Bank
    • About Us
      • About Us
      • Contact Us
      • Advertise With Us
      • Privacy Policy
      • Terms of Use
    Breaking News

    FDA Leaders Address Drug Shortages

    Acting Commish Ned Sharpless and CDER director Janet Woodcock release statement on FDA's new report about root causes and solutions to drug shortages.

    Related CONTENT
    • Mogene
    • Contract Pharma’s 20th Anniversary Series: CDMO Insight
    • Aptar’s Activ-Blister Packaging Solution Approved for HIV Drug
    • Vetio Animal Health
    • Supply Chain Disruptions
    10.30.19
    One of the U.S. Food and Drug Administration's top priorities is to ensure that Americans have access to safe and effective medicines. Sometimes, for a number of reasons, shortages of certain medicines occur and the FDA works immediately with our public health partners and industry to minimize their impact on patients and restore the availability of these drugs. A shortage of just one critical drug can have a major impact on a patient's health, which underscores why government and industry need to act quickly to prevent future shortages.
     
    Despite public and private sector efforts to prevent and mitigate drug shortages, they continue to occur and persist. So, at the request of Congress last year, the FDA convened an inter-agency Drug Shortages Task Force to study the problem, determine the root causes of drug shortages, and make recommendations for enduring solutions. This effort was designed to help address the number of drug shortages that we continue to experience, which place a serious burden on patients and providers who need access to these medically necessary products.
     
    To understand forces causing drug shortages, the Task Force commissioned a team of FDA economists and scientists to analyze drugs that went into shortage from 2013 to 2017. The agency also invited public participation by hosting a public meeting, opening a docket to receive public comments, and inviting stakeholders from industry, academia, and the medical provider and patient communities to a series of listening sessions to provide insight into the causes of drug shortages and identify potential solutions.
     
    Today, on behalf of the inter-agency Task Force, the FDA issued a report, "Drug Shortages: Root Causes and Potential Solutions," that attempts to identify root causes and offer recommendations for government and industry based on insights gleaned from stakeholders in the private and public sectors. These recommendations are intended to help prevent and mitigate future drug shortages. The report focuses on human drugs, but many of the same concerns apply to veterinary medicines used to treat service, companion, and food-producing animals.
     
    The Task Force found that the number of ongoing drug shortages has been rising, and that their impact is likely underappreciated. The Task Force analyzed 163 drugs that went into shortage from 2013 to 2017 and compared these medicines to similar drugs that did not go into shortage. Shortage drugs were more likely to be relatively low-price and financially unattractive drugs and were more likely to be sterile injectables. Shortages often occurred as a result of disruption in supply due to a variety of factors. Importantly, prices rarely rose after shortages began, and during shortages, production typically did not increase enough to restore supply to pre-shortage levels. Many manufacturers reported discontinuing the production of drugs before a shortage for commercial reasons (e.g., loss of profitability). These results suggest a broken marketplace, where scarcity of drugs in shortage or at risk for shortage does not result in the price increases predicted by basic economic principles. While there are no easy solutions to the problems identified, and there is no single cause of drug shortages, the Task Force offers three key recommendations to address the root causes of shortages.
     
    First, we recommend taking steps to increase understanding of the impacts of drug shortages and companies' contracting practices that may contribute to them. Currently, there is little private or public sector effort to collect and analyze comprehensive information to characterize shortages, quantify their effects, or closely observe the contracting practices that may be driving them. This information would help improve stakeholders' understanding of the impact shortages have on the Nation's health care and support private and public-sector strategies to prevent or mitigate them in the future. Our report encourages more systematic and transparent study of current contracting practices to support development of model contracts designed to promote reliable access to safe, effective, and affordable drugs.
     
    Second, we support the idea of developing a system to measure and rate a facility's quality management maturity. The rating would evaluate the robustness of a manufacturing facility's quality system and its ability to deliver high-quality products reliably and without disruption. Historically, many pharmaceutical manufacturing firms have focused their efforts on compliance with Current Good Manufacturing Practices (CGMPs), which set a minimum threshold that companies must achieve to be allowed to supply the U.S. marketplace. They do not include more advanced levels of quality management. As outlined in an FDA Voices perspective piece issued last week, a rating system could be used to inform purchasers, group purchasing organizations (GPOs), and consumers about the state of, and commitment to, the quality management maturity of the manufacturing facility making the drugs they are buying. This effort would introduce transparency into the market, and provide companies committed to quality management maturity with a competitive advantage, potentially enabling them to obtain sustainable prices as well as grow market share.
     
    Third, we recommend considering new contracting approaches that help ensure a reliable supply of drugs. This may include providing financial incentives to make certain that manufacturers, especially of older generic drugs, earn sustainable returns on their products. The combination of more complete information about contracting practices and greater transparency of the quality management maturity of specific manufacturing sites would enable payers, purchasers, and GPOs to consider new contracting approaches aimed at making sure there is a reliable supply of medically important drugs. This could be done through several different mechanisms, such as paying higher prices for drugs manufactured at top-rated facilities, requiring a certain quality maturity rating as a condition of contracting, or guaranteeing purchase of a set volume of products from sites achieving a certain quality maturity rating.
     
    The report also describes several legislative proposals and planned FDA initiatives that focus primarily on enabling the agency to help prevent supply disruptions that lead to shortages. These include new requests in the President's FY 2020 budget and new guidances that the agency intends to release by the end of calendar year 2019. We have outlined these specific actions in the report, and they are designed to mitigate and prevent drug shortages nationwide.
     
    We also feel that international action is necessary. The International Council for Harmonisation (ICH) is finalizing a guideline, "ICH Guideline Q12: Technical and Regulatory Considerations for Pharmaceutical Product Lifecycle Management," which provides opportunities for regulatory flexibility in making post-approval changes to the product or its manufacturing process. Global implementation of this guideline, once finalized, could facilitate the efforts of manufacturers for the international market who wish to modernize processes and equipment to avoid potential disruptions, but have found the regulatory landscapes of different countries to pose a financial burden.
     
    Given the potential scale of impacts from drug shortages, and the fact that these impacts have continually been underestimated, it is likely that drug shortages will continue to persist absent major changes to this marketplace. The root causes of shortages involve economic factors that are driven by both private- and public-sector decision-making. This means that the types of enduring solutions proposed in the report will require multi-stakeholder efforts and rethinking business practices throughout all sectors of the health care system. It will also require a fuller characterization of the true costs of shortages and more comprehensive and reliable analysis of the effects shortages have on patients and the health care system.
     
    We hope that the recommendations set forth in this report will help to set a framework that all stakeholders can assess and implement as we work together to further mitigate the public health impact that drug shortages have on American consumers. In the meantime, the FDA's employees remain committed to working behind-the-scenes to anticipate and help mitigate shortages and make sure that patients have access to the drugs they need. The FDA will continue to report regularly on the progress of our Task Force and keep the public informed about current drug shortages and our efforts to prevent and mitigate new ones.
     
    —Norman E. "Ned" Sharpless MD, Acting Commissioner of FDA
    —Janet Woodcock MD, Director - Center for Drug Evaluation and Research (CDER)
    Related Searches
    • study
    • Development
    • fda
    • Manufacturing
    Suggested For You
    Mogene Mogene
    Contract Pharma’s 20th Anniversary Series: CDMO Insight Contract Pharma’s 20th Anniversary Series: CDMO Insight
    Aptar’s Activ-Blister Packaging Solution Approved for HIV Drug Aptar’s Activ-Blister Packaging Solution Approved for HIV Drug
    Vetio Animal Health Vetio Animal Health
    Supply Chain Disruptions Supply Chain Disruptions
    LSNE LSNE's Spain Site Gets FDA Approval
    Civica Rx and Exela Pharma Sciences Join Forces to Supply Sodium Bicarbonate Civica Rx and Exela Pharma Sciences Join Forces to Supply Sodium Bicarbonate
    Continuous Manufacturing and its Regulatory Challenge Continuous Manufacturing and its Regulatory Challenge
    Knowledge Sharing: Biologics Development and Delivery Knowledge Sharing: Biologics Development and Delivery
    FDA Approves Antibiotic for Community-Acquired Pneumonia FDA Approves Antibiotic for Community-Acquired Pneumonia
    Embracing Risk-Based Monitoring: The Pivotal Role of Tools and Technologies  Embracing Risk-Based Monitoring: The Pivotal Role of Tools and Technologies
    Syapse, FDA Announce RCA Using Real-World Evidence Syapse, FDA Announce RCA Using Real-World Evidence
    Boehringer Ingelheim, MD Anderson Form Virtual Cancer R&D Center Boehringer Ingelheim, MD Anderson Form Virtual Cancer R&D Center
    Avomeen Appoints Project Director of Biological Chemistry Avomeen Appoints Project Director of Biological Chemistry
    Hikma, Civica Rx Ink Generic Drug Shortage Deal Hikma, Civica Rx Ink Generic Drug Shortage Deal

    Related Buyers Guide Companies

    • Mogene

      ...
      Craig Morley, CEO 11.17.20

    • cGMP Manufacture | Drug Development
      Contract Pharma’s 20th Anniversary Series: CDMO Insight

      Contract Pharma’s 20th Anniversary Series: CDMO Insight

      JoyL Silva of Pfizer CentreOne discusses global market and regulatory changes driving drug development strategies and the evolution of CDMO services and ops.
      Kristin Brooks, Contract Pharma 11.01.19

    • Breaking News | Packaging & Tracking | Solid Dosage/Semi-solids
      Aptar’s Activ-Blister Packaging Solution Approved for HIV Drug

      Aptar’s Activ-Blister Packaging Solution Approved for HIV Drug

      System protects oral solid drug products with a 3-Phase Activ-Polymer solution, including moisture adsorption, oxygen and odor scavenging.
      10.24.19


    • Vetio Animal Health

      Vetio Animal Health

      ...
      John Kane, CEO 10.24.19

    • Supply Chain
      Supply Chain Disruptions

      Supply Chain Disruptions

      The implications of Sandoz’ recent recalls.
      Ed Silverman, Guest Columnist 10.15.19

    Loading, Please Wait..
    Trending
    • Gilead Sciences To Acquire MiroBio For $405M
    • Amgen To Acquire ChemoCentryx For $3.7B
    • BioNTech, Genmab Expand Global Strategic Oncology Collaboration
    • Bayer Opens New Research And Innovation Center At Kendall Square
    • Datwyler To Double Capacity At Production Ops In Pune
    Breaking News
    • BioIVT Acquires Scottish Drug-metabolizing Enzyme Manufacturer Cypex
    • Schott Creates Stand-Alone Company for its Pharma Business
    • Marken to Acquire Medical Courier Business of Cedra Express
    • Porton’s New Crystallization and Drug Product Facility
    • Thermo Fisher Expands NY Cell Culture Media Manufacturing Site
    View Breaking News >
    CURRENT ISSUE

    July/August 2022

    • Biotechnology’s Role in Improving Stroke Outcomes
    • CEO Spotlight: Marc Kikuchi
    • View More >

    Cookies help us to provide you with an excellent service. By using our website, you declare yourself in agreement with our use of cookies.
    You can obtain detailed information about the use of cookies on our website by clicking on "More information”.

    • About Us
    • Privacy Policy
    • Terms And Conditions
    • Contact Us

    follow us

    Subscribe
    Nutraceuticals World

    Latest Breaking News From Nutraceuticals World

    3i Solutions Announces New Leadership Positions
    INS Nutra Opens Gummy Manufacturing Facility
    Vital Nutrients Launches First Vegan Omega Supplement with SPMs
    Coatings World

    Latest Breaking News From Coatings World

    Custom Cars Featuring PPG DELTRON Refinish System Take Awards at Goodguys 24th Summit
    HGTV Home by Sherwin-Williams Announces 2023 Color Collection of the Year
    BASF to Produce More Specialty Pyrrolidones in North America
    Medical Product Outsourcing

    Latest Breaking News From Medical Product Outsourcing

    Elizabeth Coleon Joins Withings as Chief Marketing Officer
    U.K. Strengthens Medical Device Regulations
    Fujirebio Acquires ADx NeuroSciences
    Contract Pharma

    Latest Breaking News From Contract Pharma

    BioIVT Acquires Scottish Drug-metabolizing Enzyme Manufacturer Cypex
    Schott Creates Stand-Alone Company for its Pharma Business
    Marken to Acquire Medical Courier Business of Cedra Express
    Beauty Packaging

    Latest Breaking News From Beauty Packaging

    The Body Shop Expands Partnership with Uber
    COSRX Launches Vitamin E Vitalizing Sunscreen
    Weekly Recap: Kylie Makeup Lab Controversy, Glossier Pivots to Retail and Wholesale & More
    Happi

    Latest Breaking News From Happi

    Dry Shampoo Brand Batiste Teams Up with Barry's Boot Camp to Give Consumers Post-Workout Refresh
    Watsons China Launches Health Care Zone Prompted by the Covid-19 Pandemic
    Earth Therapeutics Celebrates National CBD Day with Foot Balm-Enriched CBD
    Ink World

    Latest Breaking News From Ink World

    Weekly Recap: Zeller+Gmelin, Epple Druckfarben Lead This Week’s News Stories
    A-Flex Label Adds Epson SurePress UV Digital Label Press
    Ball Announces 2Q 2022 Results
    Label & Narrow Web

    Latest Breaking News From Label & Narrow Web

    Eukalin acquires Adhesives Specialists
    EyeC unveils new inspection products
    Errol Moebius named VP of IST America
    Nonwovens Industry

    Latest Breaking News From Nonwovens Industry

    Weekly Recap: A New Day for Hygiene, Glatfelter Reports Q2 Results & More
    Dyper Achieves B Corp Certification
    Edgewell’s Sales Grow
    Orthopedic Design & Technology

    Latest Breaking News From Orthopedic Design & Technology

    NuVasive Inc. Reports Q2 2022 Financial Results
    Solid Growth Ahead for Carpal Tunnel Release Systems Sector
    ODT's Most-Read Stories This Week—Aug. 6
    Printed Electronics Now

    Latest Breaking News From Printed Electronics Now

    Weekly Recap: STMicroelectronics, NextFlex and onsemi Top This Week’s Stories
    Zebra Technologies Reports 2Q 2022 Results
    InnovationLab Demonstrates New PCB Production Method Based on Additive Manufacturing

    Copyright © 2022 Rodman Media. All rights reserved. Use of this constitutes acceptance of our privacy policy The material on this site may not be reproduced, distributed, transmitted, or otherwise used, except with the prior written permission of Rodman Media.

    AD BLOCKER DETECTED

    Our website is made possible by displaying online advertisements to our visitors.
    Please consider supporting us by disabling your ad blocker.


    FREE SUBSCRIPTION Already a subscriber? Login